Illumina (ILMN) Stock Price, News & Analysis

Company Overview

Illumina, Inc. is a leading developer, manufacturer and marketer of life science tools and integrated systems for large‐scale analysis of genetic variation and function. Founded in 1998 and headquartered in San Diego, California, the company pioneered next-generation sequencing (NGS) technology that has accelerated research in genomics and transformed applications in diagnostics, agriculture and drug development. Its flagship platforms include the NovaSeq, NextSeq and MiSeq systems, which enable high-throughput sequencing for whole-genome, exome and targeted panels.

In addition to sequencing instruments, Illumina offers a broad portfolio of microarray products, consumables, software and services designed to support diverse workflows from sample preparation through data analysis. The company’s reagent kits and flow cells ensure high accuracy and reproducibility, while its BaseSpace Sequence Hub provides a cloud-based environment for data management, secondary analysis and collaboration. These integrated solutions serve customers in academic institutions, clinical laboratories, pharmaceutical companies and agricultural research centers worldwide.

Illumina’s technologies have underpinned major scientific projects such as the Human Genome Project follow-on studies, large-scale population genomics initiatives and precision medicine programs. By enabling rapid, cost-effective genomic data generation, the company has opened new avenues in oncology, prenatal testing, rare disease research and microbial genomics. Collaborations with leading healthcare providers and research consortia further extend the reach of its diagnostic and therapeutic applications.

Governed by a seasoned leadership team and board of directors, Illumina is led by President and Chief Executive Officer Francis deSouza, who has guided the company through significant product launches and strategic partnerships. With operational centers in North America, Europe and Asia-Pacific, Illumina maintains a global footprint that supports local market needs while fostering innovation through regional R&D hubs. The company continues to invest in expanding its technological capabilities to address emerging challenges in genomics and personalized medicine.

Key Stats

• Today's Range: $97.04 to $100.25
• 50-Day Range: $74.53 to $100.44
• 52-Week Range: $68.70 to $156.66
• Volume: 1.89 million shs
• Average Volume: 2.14 million shs
• Market Capitalization: $15.71 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $127.42
• Consensus Rating: Moderate Buy

Illumina Stock Analysis - MarketRank™

Illumina scored higher than 97% of companies evaluated by MarketBeat, and ranked 42nd out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Illumina has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 9 buy ratings, 9 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Illumina has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 14.41%

Earnings Growth

Earnings for Illumina are expected to grow by 14.41% in the coming year, from $4.51 to $5.16 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Illumina is -16.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Illumina is -16.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Illumina has a PEG Ratio of 1.91. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Illumina has a P/B Ratio of 6.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.09% of the float of Illumina has been sold short.

Short Interest Ratio / Days to Cover

Illumina has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Illumina has recently increased by 14.96%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Illumina does not currently pay a dividend.

Dividend Growth

Illumina does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -1.11

Percentage of Shares Shorted

4.09% of the float of Illumina has been sold short.

Short Interest Ratio / Days to Cover

Illumina has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Illumina has recently increased by 14.96%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 1.56

News Sentiment

Illumina has a news sentiment score of 1.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 17 news articles for Illumina this week, compared to 18 articles on an average week.

Search Interest

Only 16 people have searched for ILMN on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

MarketBeat Follows

6 people have added Illumina to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Illumina insiders have bought more of their company's stock than they have sold. Specifically, they have bought $495,381.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 0.17% of the stock of Illumina is held by insiders.

Percentage Held by Institutions

89.42% of the stock of Illumina is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ILMN Stock Analysis - Frequently Asked Questions

How have ILMN shares performed this year?

Illumina's stock was trading at $133.63 on January 1st, 2025. Since then, ILMN stock has decreased by 25.7% and is now trading at $99.27.

How were Illumina's earnings last quarter?

Illumina, Inc. (NASDAQ:ILMN) released its quarterly earnings data on Thursday, May, 8th. The life sciences company reported $0.97 EPS for the quarter, topping analysts' consensus estimates of $0.96 by $0.01. The firm's revenue was down 1.4% compared to the same quarter last year.
Read the conference call transcript.

Does Illumina have any subsidiaries?

The following companies are subsidiaries of Illumina: Grail, Enancio, BlueBee, Edico Genome, Conexio Genomics, GenoLogics, NextBio, and more.

Who are Illumina's major shareholders?

Top institutional investors of Illumina include Douglas Lane & Associates LLC (0.18%), Partnership Wealth Management LLC (0.01%), Kera Capital Partners Inc. and OMNI 360 Wealth Inc.. Insiders that own company stock include Susan H Tousi, Jacob Thaysen, Aimee L Hoyt and Alexander Aravanis.
View institutional ownership trends.

How do I buy shares of Illumina?

Shares of ILMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Illumina own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Illumina investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), Visa (V) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/09/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:ILMN
• CIK: 1110803
• Web: www.illumina.com
• Phone: (858) 202-4500
• Fax: 858-202-4766
• Employees: 9,030
• Year Founded: 1998

Price Target and Rating

• Average Price Target for Illumina: $127.42
• High Price Target: $200.00
• Low Price Target: $85.00
• Potential Upside/Downside: +28.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 20 Analysts

Profitability

• EPS (Trailing Twelve Months): ($6.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 22.01
• P/E Growth: 1.91
• Net Income: -$1.22 billion
• Net Margins: -22.25%
• Pretax Margin: -20.48%
• Return on Equity: 25.54%
• Return on Assets: 8.62%

Debt

• Debt-to-Equity Ratio: 0.63
• Current Ratio: 1.86
• Quick Ratio: 1.48

Sales & Book Value

• Annual Sales: $4.37 billion
• Price / Sales: 3.59
• Cash Flow: $4.79 per share
• Price / Cash Flow: 20.71
• Book Value: $14.96 per share
• Price / Book: 6.64

Miscellaneous

• Outstanding Shares: 158,300,000
• Free Float: 158,031,000
• Market Cap: $15.71 billion
• Optionable: Optionable
• Beta: 1.36